This case-control study examined cancer risk in carriers of pathogenic or likely pathogenic PALB2 variants found by exome sequencing. It used UK Biobank (469,580 adults) and Geisinger MyCode (167,050), with cancers and deaths from linked registry and health records. Carrier prevalence was 1 in 940 in MyCode and 1 in 571 in UK Biobank, raised by a founder variant. Carriers had raised odds of pancreatic cancer and hazard ratios of 1.7 to 3.6 for any and female breast cancer. All-cause mortality was raised (hazard ratio 1.61 to 1.67), and survival after a cancer diagnosis was lower. These risks were lower than estimates from people ascertained through a personal or family history of cancer.
Why it is interesting: Most PALB2 risk estimates come from people ascertained through a personal or family history of cancer. Sequencing whole population cohorts gives lower but still raised cancer risks and higher mortality.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.